{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:27:00Z","timestamp":1782552420829,"version":"3.54.5"},"reference-count":36,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>There is a dearth of published literature comparing glucose variability (GV) between different insulin regimens in type 2 diabetes. This cohort study compares GV using continuous glucose monitoring (CGM) in patients with well-controlled type 2 diabetes using four common insulin regimens: basal insulin + oral drugs (BO), basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), premixed insulin (PM), and basal-bolus insulin (BB).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Consecutive patients from three endocrinology clinics who met study criteria\u2014type 2 diabetes, age 18 to 80 years, BMI \u2264 45 kg\/m2, stable insulin regimen for a minimum of 6 months, and stable A1C value \u22647.5% (58 mmol\/mol) before study enrollment\u2014underwent 6-day masked CGM. Hypoglycemia was defined as a sensor glucose concentration &amp;lt;70 mg\/dL on CGM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A total of 160 patients with comparable baseline characteristics formed four equal insulin regimen cohorts. The daily glucose SD (the primary outcome) was significantly lower in the BGLP cohort versus the BO, PM, and BB cohorts (P = 0.03, P = 0.01, and P &amp;lt; 0.01, respectively), and remained so after adjusting for age, BMI, type 2 diabetes duration, and A1C. Similarly, daily hypoglycemia outcomes on CGM were least for the BGLP cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The lowest GV and lowest hypoglycemia were observed in patients using the combination of basal insulin with a GLP-1 RA, supporting the complementary glycemic action of these agents in type 2 diabetes. These observed benefits in GV and hypoglycemia may contribute to the cardiovascular outcome reduction seen with GLP-1 RA therapy and should be investigated further.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-1582","type":"journal-article","created":{"date-parts":[[2016,12,3]],"date-time":"2016-12-03T02:50:26Z","timestamp":1480733426000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":58,"title":["Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)"],"prefix":"10.2337","volume":"40","author":[{"given":"Harpreet S.","family":"Bajaj","sequence":"first","affiliation":[{"name":"LMC Diabetes & Endocrinology, Brampton, Ontario, Canada"},{"name":"Leadership Sinai Center for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karri","family":"Venn","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avril","family":"Patrick","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Kalra","sequence":"additional","affiliation":[{"name":"Royal College of Surgeons, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnain","family":"Khandwala","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Etobicoke, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Aslam","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Etobicoke, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Twum-Barima","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Oakville, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Aronson","sequence":"additional","affiliation":[{"name":"LMC Diabetes & Endocrinology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,12,2]]},"reference":[{"key":"2022031301541328800_B1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2022031301541328800_B2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031301541328800_B3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2337\/dc06-1610","article-title":"The effect of glucose variability on the risk of microvascular complications in type 1 diabetes","volume":"30","author":"Hirsch","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2337\/db08-0063","article-title":"Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients","volume":"57","author":"Ceriello","year":"2008","journal-title":"Diabetes"},{"key":"2022031301541328800_B5","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2337\/dc06-0293","article-title":"The effect of glucose variability on the risk of microvascular complications in type 1 diabetes","volume":"29","author":"Kilpatrick","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.diabet.2008.04.005","article-title":"Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?","volume":"34","author":"Bragd","year":"2008","journal-title":"Diabetes Metab"},{"key":"2022031301541328800_B7","doi-asserted-by":"crossref","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"key":"2022031301541328800_B8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/193229680700100111","article-title":"Optimizing display, analysis, interpretation and utility of self-monitoring of blood glucose (SMBG) data for management of patients with diabetes","volume":"1","author":"Rodbard","year":"2007","journal-title":"J Diabetes Sci Technol"},{"key":"2022031301541328800_B9","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"2022031301541328800_B10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and \u03b1- and \u03b2-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"2022031301541328800_B11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"2022031301541328800_B12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc09-2191","article-title":"Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study","volume":"33","author":"Arnolds","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B13","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B14","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2337\/dc15-2782","article-title":"Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk","volume":"39","author":"FLAT-SUGAR Trial Investigators","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/dia.2013.0051","article-title":"Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP)","volume":"15","author":"Bergenstal","year":"2013","journal-title":"Diabetes Technol Ther"},{"key":"2022031301541328800_B17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2009-0021","article-title":"Glucose variability; does it matter?","volume":"31","author":"Siegelaar","year":"2010","journal-title":"Endocr Rev"},{"key":"2022031301541328800_B18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s13300-011-0005-0","article-title":"Emerging role of insulin with incretin therapies for management of type 2 diabetes","volume":"2","author":"Ahluwalia","year":"2011","journal-title":"Diabetes Ther"},{"key":"2022031301541328800_B19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301541328800_B20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/dom.12473","article-title":"Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031301541328800_B21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.metabol.2008.10.018","article-title":"Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects [published correction appears in Metabolism 2009;58:1046]","volume":"58","author":"Razavi Nematollahi","year":"2009","journal-title":"Metabolism"},{"key":"2022031301541328800_B22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc10-0013","article-title":"Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes","volume":"33","author":"Wright","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2337\/dc09-0354","article-title":"Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals","volume":"33","author":"Gogitidze Joy","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B24","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.hjr.0000368193.24732.66","article-title":"Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes","volume":"17","author":"Ceriello","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2022031301541328800_B25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.295.14.1681","article-title":"Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes","volume":"295","author":"Monnier","year":"2006","journal-title":"JAMA"},{"key":"2022031301541328800_B26","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2337\/db12-0224","article-title":"Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes","volume":"61","author":"Ceriello","year":"2012","journal-title":"Diabetes"},{"key":"2022031301541328800_B27","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.2337\/db13-0468","article-title":"Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk","volume":"63","author":"Chow","year":"2014","journal-title":"Diabetes"},{"key":"2022031301541328800_B28","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/eurheartj\/eht332","article-title":"Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial","volume":"34","author":"Mellbin","year":"2013","journal-title":"Eur Heart J"},{"key":"2022031301541328800_B29","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc12-2469","article-title":"Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes","volume":"36","author":"Ceriello","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B30","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc13-2618","article-title":"Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes","volume":"37","author":"Ceriello","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301541328800_B31","doi-asserted-by":"crossref","first-page":"e83758","DOI":"10.1371\/journal.pone.0083758","article-title":"Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia","volume":"9","author":"Gejl","year":"2014","journal-title":"PLoS One"},{"key":"2022031301541328800_B32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031301541328800_B33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/152091503763816427","article-title":"Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring","volume":"5","author":"Hay","year":"2003","journal-title":"Diabetes Technol Ther"},{"key":"2022031301541328800_B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031301541328800_B35","unstructured":"National Institutes of Health. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2016. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01394952. Accessed 2 July 2016"},{"key":"2022031301541328800_B36","unstructured":"National Institutes of Health. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2016. Available from http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01144338. Accessed 2 July 2016"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/2\/194\/547920\/dc161582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/2\/194\/547920\/dc161582.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:58:46Z","timestamp":1647151126000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/2\/194\/37026\/Lowest-Glucose-Variability-and-Hypoglycemia-Are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,12,2]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-1582","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}